Cost-Effectiveness Analysis of Pneumococcal Vaccination with the Pneumococcal Polysaccharide NTHi Protein D Conjugate Vaccine in the Philippines

Zhang, Xuhao; Nievera, Maria Carmen; Carlos, Josefina; Lucero, Marilla; Bibera, Gyneth Lourdes; Atienza, Maria Isabel; Topachevskyi, O.; Navarro-Locsin, Cecilia Gretchen

doi:10.1016/j.vhri.2014.04.004

Cited by 19 publications

(36 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PHiD-CV 2+1 was predicted to be dominant over PCV13 2+1. This dominance is in line with various other cost-effectiveness analyses, from Malaysia [ 10 ], Japan [ 57 ], the Philippines [ 27 ], Turkey [ 58 ], Europe [ 20 , 59 – 61 ], Canada [ 20 ] and Peru [ 53 ]. However, some studies have predicted the reverse: that PCV13 would be dominant over PHiD-CV (Malaysia and Hong Kong [ 11 ], Colombia [ 62 ], Europe [ 63 ] and Canada [ 64 ]) or more cost-effective than PHiD-CV (Peru [ 65 ]).…”

Section: Discussionsupporting

confidence: 81%

“…Age-specific AOM GP consultation rates (Additional file 1 : Table S3) were based on published data from the Philippines [ 27 ] due to the lack of Malaysian data. Myringotomy rates (Additional file 1 : Table S3) were adapted from data from the Philippines [ 27 ] that were based on insurance data from Taiwan [ 26 ] and consultation with local ear, nose and throat experts. In the base case, all cases of AOM were assumed to result in a GP consultation.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

Wang

Saha²,

Zhang

2017

Cost Eff Resour Alloc

Self Cite

View full text Add to dashboard Cite

BackgroundCurrently, two pediatric pneumococcal conjugate vaccines are available in the private market of Malaysia—13-valent pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide and non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV). This study aimed to evaluate the cost-effectiveness of a universal mass vaccination program with a PHiD-CV 2+1 schedule versus no vaccination or with a PCV13 2+1 schedule in Malaysia.MethodsA published Markov cohort model was adapted to evaluate the epidemiological and economic consequences of programs with no vaccination, a PHiD-CV 2+1 schedule or a PCV13 2+1 schedule over a 10-year time horizon. Disease cases, deaths, direct medical costs, quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratios (ICERs) were estimated. Locally published epidemiology and cost data were used whenever possible. Vaccine effectiveness and disutility data were based on the best available published data. All data inputs and assumptions were validated by local clinical and health economics experts. Analyses were conducted from the perspective of the Malaysian government for a birth cohort of 508,774. Costs and QALYs were discounted at 3% per annum. One-way and probabilistic sensitivity analyses were performed.ResultsCompared with no vaccination, a PHiD-CV 2+1 program was projected to prevent 1109 invasive pneumococcal disease (IPD), 24,679 pneumonia and 72,940 acute otitis media (AOM) cases and 103 IPD/pneumonia deaths over 10 years, with additional costs and QALYs of United States dollars (USD) 30.9 million and 1084 QALYs, respectively, at an ICER of USD 28,497/QALY. Compared with a PCV13 2+1 program, PHiD-CV 2+1 was projected to result in similar reductions in IPD cases (40 cases more) but significantly fewer AOM cases (30,001 cases less), with cost savings and additional QALYs gained of USD 5.2 million and 116 QALYs, respectively, demonstrating dominance over PCV13. Results were robust to variations in one-way and probabilistic sensitivity analyses.ConclusionsA PHiD-CV 2+1 universal mass vaccination program could substantially reduce pneumococcal disease burden versus no vaccination, and was expected to be cost-effective in Malaysia. A PHiD-CV 2+1 program was also expected to be a dominant choice over a PCV13 2+1 program in Malaysia.Electronic supplementary materialThe online version of this article (doi:10.1186/s12962-017-0079-2) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Methodsmentioning

confidence: 99%

Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

Wang

Saha²,

Zhang

2017

Cost Eff Resour Alloc

Self Cite

View full text Add to dashboard Cite

show abstract

“…The majority of the studies (n = 10) compared the potential benefits of two newer versions of PCV, namely PCV-10 and PCV-13 [20,25,28,31,34,36,37,42,44,47]. Seven studies assessed the cost-effectiveness of PCV-7 [27,29,30,32,33,39,46], of which one study assessed its effectiveness in the context of typical and pandemic influenza seasons [30].…”

Section: Methodsmentioning

confidence: 99%

“…The included studies were conducted in 11 Asian countries, including China (n = 7) [26,30,32,33,35,41,48] Malaysia (n = 3) [34,42,44], Hong Kong (n = 3) [28,29,42] Korea (n = 2) [25,46], The Philippines (n = 2) [31,36],Taiwan (n = 2) [27,43], Japan (n = 3) [20,38,39], Thailand (n = 1) [47], Mongolia (n = 1) [45], Bhutan (n = 1) [37], and India (n = 1) [40] (Table 1). One study was a multiple country analysis, performed in Malaysia and Hong Kong [42].…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies

et al. 2020

View full text Add to dashboard Cite

Background: Evidence on costs and health benefits of pneumococcal conjugate vaccine (PCV) for children in Asian countries is limited but growing. As a region with a considerably high burden of pneumococcal disease, it is prominent to have a comprehensive overview on the cost-effectiveness of implementing and adopting a PCV vaccination program. Methods: We conducted a systematic review from Pubmed and Embase to identify economic evaluation studies of PCV for children in Asian countries up to May 2020. Data extraction included specific characteristics of the study, input parameters, cost elements, cost-effectiveness results, and key drivers of uncertainty. The Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) statement was followed for this systematic review. The reporting quality of the included studies was evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Results: After the screening process on both the title and abstract and full text of 518 records, a total of 25 studies fulfilled the inclusion criteria, and were included in the review. The majority of included studies demonstrates that PCV for children is cost-effective in most of the Asian region, and even cost-saving in some countries. Most of the included studies implemented cost utility analysis (CUA) using either quality-adjusted life years (QALYs) or disability-adjusted life years (DALYs). Overall, the main drivers affecting the cost effectiveness were vaccine price, burden regarding pneumonia-related parameters, and the inclusion of herd effects. Conclusion: The children pneumococcal vaccination program appears to be a cost-effective intervention in Asia, and even cost-saving in certain conditions. Vaccine price, pneumonia-related disease burden, and the inclusion of the herd effect are observed as important key drivers in estimating cost-effectiveness in this region. Incorporating PCV in vaccination programs in this region was found to be highly favorable.

show abstract

“…Costs were sourced from publically available country-specific tariffs (Table 2 ). Both costs and benefits were discounted at annual rates recommended by local guidelines (China: 6.0%; Peru: 3.0%; and Estonia, Russia, South Africa, India, and the Philippines: 5.0%) [ 27 – 29 ].…”

Section: Methodsmentioning

confidence: 99%

Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

Smare

Kambili

et al. 2017

BMC Health Serv Res

View full text Add to dashboard Cite

BackgroundLess than one-third of patients who are estimated to be infected with multidrug-resistant tuberculosis (MDR-TB) receive MDR-TB treatment regimens, and only 48% of those who received treatment have successful outcomes. Despite current regimens, newer, more effective and cost-effective approaches to treatment are needed. The aim of the study was to project health outcomes and impact on healthcare resources of adding bedaquiline to the treatment regimen of MDR-TB in selected high burden countries: Estonia, Russia, South Africa, Peru, China, the Philippines, and India.MethodsThis study adapted an existing Markov model to estimate the health outcomes and impact on total healthcare costs of adding bedaquiline to current MDR-TB treatment regimens. A price threshold analysis was conducted to determine the price range at which bedaquiline would be cost-effective.ResultsAdding bedaquiline to the background regimen (BR) resulted in increased disability-adjusted life years (DALYs) averted, and reduced total healthcare costs (excluding treatment acquisition costs) compared with BR alone in all countries analyzed. Addition of bedaquiline to BR resulted in savings to healthcare costs compared with BR alone in all countries analyzed, with the highest impact expected in Russia (US$194 million) and South Africa (US$43 million). The price per regimen at which bedaquiline would be cost-effective ranged between US$23,904-US$203,492 in Estonia, Russia, Peru, South Africa, and China (high and upper middle-income countries) and between US$6,996-US$20,323 in the Philippines and India (lower middle-income countries); however, these cost-effective prices do not necessarily address concerns about affordability.ConclusionsAdding bedaquiline to BR provides improvements in health outcomes and reductions in healthcare costs in high MDR-TB burden countries. The range of prices per regimen for which bedaquiline would be cost-effective varied between countries.Electronic supplementary materialThe online version of this article (doi:10.1186/s12913-016-1931-3) contains supplementary material, which is available to authorized users.

show abstract

Cost-Effectiveness Analysis of Pneumococcal Vaccination with the Pneumococcal Polysaccharide NTHi Protein D Conjugate Vaccine in the Philippines

Abstract: The PHiD-CV 2 + 1 UMV program is projected to be cost-effective, compared with no vaccination, and would provide substantial savings with higher quality-adjusted life-year gains as compared with the PCV13 2 + 1 strategy in the context of the Philippines.

Cited by 19 publications

References 24 publications

Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia

Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies

Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

Contact Info

Product

Resources

About